Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 29, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in orphazymes shares made
Read moreOrphazyme completes rolling submission of New Drug Application to U.S. FDA for arimoclomol for Niemann-Pick disease Type C
Jul 20, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that it has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational therapy arimoclomol for the treatment of Niemann-Pick disease Type C (NPC).
Orphazyme completes rolling submission of new drug
Read moreOrphazyme to collaborate with The Michael J. Fox Foundation on Parkinson’s disease research
Jul 17, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that it will join The Michael J. Fox Foundation’s (MJFF) Parkinson’s Disease Research Tools Consortium. The group brings together experts from the medical community and industry to identify and develop new pre-clinical tools to address unmet research needs and accelerate experiments. Orphazyme’s drug candidate arimoclomol has potential across a range of neurodegenerative diseases, including GCase-deficient Parkinson’s disease (PD).
Orphazyme to collaborate with the Michael J. Fox foundation
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 16, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme or their closely associated persons.
Reporting of transactions in orphazymes shares made
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 15, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreCapital increase of 3,451 shares in Orphazyme A/S as a result of the exercise of Restricted Share Units
Jul 7, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that a share capital increase has been registered with the Danish Business Authority as a result of the exercise of Restricted Share Units by board members. A total of 3,451 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Restricted Share Unit of DKK 61.1895.
Capital increase of 3 451 shares in Orphazyme
Read moreReporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Jul 3, 2020
Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme.
Reporting of transactions in Orphazymes shares made
Read moreNew share-based incentive program
Jul 1, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announced that the Company has introduced a new share-based incentive program (the “LTIP”) for 2020. The LTIP has been implemented in accordance with Orphazyme’s Remuneration Policy adopted at Orphazyme’s annual general meeting on March 26, 2020.
Read moreOrphazyme announces confidential submission of a draft registration statement for a potential registered public offering in the United States
Jul 1, 2020
Orphazyme A/S (ORPHA.CO) (the “Company”), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Proteins in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announced that it has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission (“SEC”) relating to a potential registered public offering of the Company’s ordinary shares, in the form of American Depositary Shares (“ADSs”), in the United States. The draft registration statement is subject to ongoing review by the SEC, and the proposed listing of ADSs representing the Company's ordinary shares is subject to approval for listing on the Nasdaq Global Market. The Company's ordinary shares will continue to be admitted for trading on Nasdaq Copenhagen. Any potential offering is subject to market and other conditions, including board approval.
Orphazyme announces confidential submission
Read moreOrphazyme phase 2 study of arimoclomol in Gaucher disease demonstrates marked improvements in key clinical markers
Jun 24, 2020
Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces topline results from a 6-month phase 2 dose-finding study in Gaucher disease with arimoclomol, an investigational Heat-Shock Protein (HSP) amplifier. The data show a dose-dependent effect of arimoclomol on certain disease-relevant clinical secondary endpoints, such as liver and spleen size. Furthermore, the data demonstrate sustained levels of arimoclomol in the cerebrospinal fluid (CSF), providing further evidence of arimoclomol’s ability to cross the blood-brain barrier.
Orphazyme phase 2 study of arimoclomol
Read more